Rejuvenate Biomed
Clinical-stage biotech focused on discovering and developing combination small-molecule therapeutics to address age-related diseases. The company uses validated AI-driven in silico screening and an in vivo C. elegans screening platform to generate combination drug candidates, advances assets through preclinical models and human clinical trials, and pursues partnerships and licensing for platform and asset development.
Industries
N/A
Nr. of Employees
small (1-50)
Rejuvenate Biomed
Agoralaan A-bis, 3590 Diepenbeek, Belgium
Patents
Pharmaceutical combination for use in age- related and/or degenerative diseases
US-12090124-B2
View Details
Pharmaceutical combination for use in age- related and/or degenerative diseases
US-12090124-B2
View DetailsProducts
RJx-01
Orally administered small-molecule combination candidate developed to improve muscle mass, strength and function in sarcopenia and related age-related indications; advanced through preclinical studies and Phase 1b and Phase 2 clinical evaluation.
RJx-01
Orally administered small-molecule combination candidate developed to improve muscle mass, strength and function in sarcopenia and related age-related indications; advanced through preclinical studies and Phase 1b and Phase 2 clinical evaluation.
Services
Partnerships and licensing of AI-driven in silico and in vivo screening platforms to third parties to support drug discovery and repurposing.
Partnerships and licensing of AI-driven in silico and in vivo screening platforms to third parties to support drug discovery and repurposing.
Expertise Areas
- AI-driven drug discovery and repurposing
- Combination small-molecule therapeutic development
- Preclinical efficacy testing (C. elegans and rodent models)
- Clinical trial design and execution (randomized, double-blind, placebo-controlled)
Key Technologies
- AI-enabled in silico screening
- C. elegans in vivo screening
- Rodent preclinical models
- Randomized double-blind placebo-controlled clinical trials
News & Updates
First patient dosed in a randomized, double-blind, placebo-controlled Phase 2 trial evaluating the lead combination candidate in older adults hospitalized for severe COPD exacerbation.
Collaboration with a cloud-native AI vendor to develop a low-code, disease-agnostic drug repurposing discovery tool and scale the company’s discovery platform capabilities.
Phase 1b randomized, placebo-controlled trial reported improvements in muscle strength, function and fatigue resistance and confirmed safety, tolerability and pharmacokinetics.
Peer-reviewed publication reporting that the combination candidate significantly increased muscle mass, strength and performance in mouse sarcopenia models.
Series B financing round closed to support clinical development of lead candidate and platform expansion.
Contracted a CDMO to manufacture clinical trial material for the lead combination candidate.
First patient dosed in a randomized, double-blind, placebo-controlled Phase 2 trial evaluating the lead combination candidate in older adults hospitalized for severe COPD exacerbation.
Collaboration with a cloud-native AI vendor to develop a low-code, disease-agnostic drug repurposing discovery tool and scale the company’s discovery platform capabilities.
Phase 1b randomized, placebo-controlled trial reported improvements in muscle strength, function and fatigue resistance and confirmed safety, tolerability and pharmacokinetics.
Peer-reviewed publication reporting that the combination candidate significantly increased muscle mass, strength and performance in mouse sarcopenia models.
Series B financing round closed to support clinical development of lead candidate and platform expansion.
Contracted a CDMO to manufacture clinical trial material for the lead combination candidate.